TiumBio Co.

Compiled by PlainTrial · August 8, 2026

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, TiumBio Co. sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting early-phase tilt upper half by trial count

TiumBio Co.: 2 sponsored US clinical trials, 2 recruiting.

TiumBio Co. sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Colorectal Cancer, with 1 trials.

TiumBio Co. is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING Phase 1

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

NCT05784688

RECRUITING Phase 1

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

NCT05204862

Phase Distribution

Phase	Trial count
Phase 1	2

Therapeutic Areas

Colorectal Cancer 1

Biliary Tract Cancer 1

Solid Tumor 1

Head and Neck Squamous Cell Carcinoma 1

Advanced Solid Tumor 1

What is open in the TiumBio Co. pipeline

2 recruiting of 2 indexed (100% open).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Colorectal Cancer (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

TiumBio Co.: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

TiumBio Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

TiumBio Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

1200 Pharma · 2 trials · 50% recruiting
1ST Biotherapeutics · 2 trials · 50% recruiting
3 Waves Wellness · 2 trials · 0% recruiting
3EO Health · 2 trials · 0% recruiting

Sponsors near 100% open enrollment (± trial volume)

AAVantgarde Bio Srl · 100% recruiting · 2 trials
Acorn Biolabs · 100% recruiting · 3 trials
Acrivon Therapeutics · 100% recruiting · 2 trials
ADARx Pharmaceuticals · 100% recruiting · 4 trials

Read our methodology - how this data is sourced, computed, and verified.

What to do with this TiumBio Co. page

2 registered trials is a research-attention snapshot, not an endorsement of TiumBio Co. or any single study.

2 of TiumBio Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
Colorectal Cancer is the condition TiumBio Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Colorectal Cancer trials
Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

TiumBio Co. pipeline card: 2 registered trials from official public datasets.Report a data error.